Travere Therapeutics, Inc.
(NASDAQ : RTRX)

( )
RTRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.97%136.250.0%$893.93m
AMGNAmgen, Inc. 1.12%247.501.5%$828.95m
GILDGilead Sciences, Inc. 0.90%63.841.0%$542.01m
VRTXVertex Pharmaceuticals, Inc. 1.23%258.591.9%$461.95m
REGNRegeneron Pharmaceuticals, Inc. 0.61%661.142.6%$422.10m
ILMNIllumina, Inc. 1.14%243.493.3%$313.80m
NVAXNovavax, Inc. -8.57%53.4275.7%$307.51m
BIIBBiogen, Inc. 3.40%199.651.8%$240.05m
BNTXBioNTech SE -2.90%163.000.0%$226.41m
SNSSSunesis Pharmaceuticals, Inc. 1.93%2.110.7%$147.50m
EXASEXACT Sciences Corp. -1.54%53.1717.7%$147.09m
TXG10X Genomics, Inc. 0.58%50.160.0%$101.29m
TECHBio-Techne Corp. -0.03%366.354.5%$100.80m
NKTXNkarta, Inc. -1.78%12.670.0%$99.26m
BMRNBioMarin Pharmaceutical, Inc. 0.56%79.724.2%$98.40m

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.